TOBRAMYCIN
Generic: TOBRAMYCIN
Lupin PharmaceuticalsManufacturer
RESPIRATORY (INHALATION)Route
TOBRAMYCINActive Substance
2017-03-22Original Approval
TOBRAMYCIN is FDA application ANDA208964, sponsored by LUPIN. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2024-02-22
Tobramycin for Injection, USP, 1.2 grams per Pharmacy Bulk Package, Rx Only, For Intravenous Use, PHARMACY BULK PACKAGE Failed Stability Specification: Water determination was found not complying with specification.
Class III2023-07-27
Tobramycin Opthalmic Solution USP, 0.3%, 5mL bottle, Rx only, Manufactured for: Alembic Pharmaceuticals, Bedminster, NJ Failed Impurities/Degradation Specifications
Top Reported Reactions
1
OFF LABEL USE
823 reports
2
PNEUMONIA
818 reports
3
DRUG INEFFECTIVE
770 reports
4
DYSPNOEA
714 reports
5
ACUTE KIDNEY INJURY
710 reports
6
INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS
625 reports
7
DEATH
501 reports
8
CONDITION AGGRAVATED
486 reports
9
COUGH
481 reports
10
INFECTION
474 reports